Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients
- 9 July 2008
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 44 (12) , 1678-1683
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancerAnnals of Oncology, 2007
- L’examen TEP au fluorodésoxyglucose-(18F) et son impact sur la décision thérapeutique en cancérologieLa Presse Médicale, 2006
- PET Scans for Decision-Making in Metastatic Renal Cell Carcinoma: A Single-Institution EvaluationOncology, 2006
- The impact of fluor‐18‐deoxyglucose‐positron emission tomography in the management of colorectal liver metastasesCancer, 2005
- Early clinical experience and impact of 18F-FDG PETNuclear Medicine Communications, 2005
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug DevelopmentClinical Cancer Research, 2005
- FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Clinical Decisions Associated With Positron Emission Tomography in a Prospective Cohort of Patients With Suspected or Known Cancer at One United States CenterJournal of Clinical Oncology, 2004
- Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrerʼs perspectiveNuclear Medicine Communications, 2002
- The Efficacy of Diagnostic ImagingMedical Decision Making, 1991